| 23.09 13:12 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 23.09 13:12 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 23.09 12:47 | MÄRKTE EUROPA/Erholungstag - Euro von schwachen PMIs belastet |
| 23.09 10:25 | Rückschlag für Astrazeneca mit Krebsmedikament in Phase-3-Studie |
| 23.09 08:47 | dpa-AFX: AstraZeneca: TROPION-Breast01 Phase III Trial Fails To Achieve Statistical Significance |
| 23.09 08:41 | dpa-AFX: CHMP Recommends AstraZeneca's Fasenra For Approval In Eosinophilic Granulomatosis With Polyangiitis |
| 23.09 08:12 | dpa-AFX: *ASTRAZENECA SAYS TROPION-BREAST01 PHASE III TRIAL FAILS TO ACHIEVE STATISTICAL SIGNIFICANCE IN FINAL OVERALL SURVIVAL |
| 23.09 08:08 | dpa-AFX: *ASTRAZENECA'S FASENRA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS |
| 19.09 14:21 | dpa-AFX: AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination |
| 18.09 10:24 | dpa-AFX: ANALYSE-FLASH: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15914 Pence |
| 18.09 10:24 | dpa-AFX: Goldman belässt Astrazeneca auf 'Buy' - Ziel 15914 Pence |
| 18.09 08:20 | dpa-AFX: AstraZeneca: Fasenra Approved By FDA To Treat Eosinophilic Granulomatosis With Polyangiitis |
| 18.09 08:02 | dpa-AFX: *ASTRAZENECA'S FASENRA APPROVED IN US FOR TREATMENT OF ADULT PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS |
| 18.09 08:02 | dpa-AFX: *ASTRAZENECA: FDA APPROVES FASENRA IN THE US FOR TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS IN ADULTS |
| 17.09 10:33 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 17.09 10:33 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 14000 Pence |
| 16.09 13:48 | dpa-AFX: AstraZeneca Reports 5-year Follow-up Data From HIMALAYA Study In Liver Cancer |
| 16.09 13:05 | dpa-AFX: *AZN : IMFINZI AND IMJUDO SHOW UNPRECEDENTED 5-YEAR SURVIVAL IN ADVANCED LIVER CANCER IN PHASE III TRIAL |
| 16.09 07:28 | dpa-AFX: ANALYSE-FLASH: UBS belässt Astrazeneca auf 'Sell' - Ziel 11300 Pence |
| 16.09 07:28 | dpa-AFX: UBS belässt Astrazeneca auf 'Sell' - Ziel 11300 Pence |
|
|
